or Try an Advanced Search...

    Technical Analysis for ELVN - Enliven Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 24.00 0.54% 0.13
    ELVN closed up 0.54 percent on Wednesday, May 15, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ELVN trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Outside Day Range Expansion 0.54%
    Wide Bands Range Expansion 0.54%
    Overbought Stochastic Strength 0.54%
    NR7 Range Contraction -2.00%
    Narrow Range Bar Range Contraction -2.00%
    Wide Bands Range Expansion -2.00%
    Gapped Up Strength -2.00%
    Older End-of-Day Signals for ELVN ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 15 hours ago
    Gap Up Closed about 16 hours ago
    2x Volume Pace about 16 hours ago
    1.5x Volume Pace about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ELVN Chart by TradingView
    Basic chart:

    Profile

    Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia

    Is ELVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Enliven Therapeutics GAAP EPS of -$0.54 beats by $0.02
    May 14 Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
    Apr 19 MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
    Apr 18 Enliven Therapeutics files to sell 6.43M shares for holders
    Apr 11 Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
    Apr 11 Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
    Apr 9 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
    Apr 9 Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),
    Mar 28 Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
    Mar 23 Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares
    See more ELVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.0
    52 Week Low 9.84
    Average Volume 359,953
    200-Day Moving Average 15.31
    50-Day Moving Average 18.56
    20-Day Moving Average 20.51
    10-Day Moving Average 23.54
    Average True Range 1.58
    RSI (14) 64.41
    ADX 28.21
    +DI 32.07
    -DI 14.67
    Chandelier Exit (Long, 3 ATRs) 20.41
    Chandelier Exit (Short, 3 ATRs) 20.71
    Upper Bollinger Bands 26.78
    Lower Bollinger Band 14.23
    Percent B (%b) 0.78
    BandWidth 61.24
    MACD Line 1.70
    MACD Signal Line 1.35
    MACD Histogram 0.3461
    Fundamentals Value
    Market Cap 989.09 Million
    Num Shares 41.2 Million
    EPS -0.92
    Price-to-Earnings (P/E) Ratio -26.09
    Price-to-Sales 0.00
    Price-to-Book 2.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 25.94
    Resistance 3 (R3) 26.00 25.42 25.61
    Resistance 2 (R2) 25.42 24.93 25.39 25.50
    Resistance 1 (R1) 24.71 24.63 24.42 24.65 25.40
    Pivot Point 24.13 24.13 23.99 24.10 24.13
    Support 1 (S1) 23.42 23.64 23.13 23.36 22.60
    Support 2 (S2) 22.84 23.34 22.81 22.50
    Support 3 (S3) 22.13 22.84 22.39
    Support 4 (S4) 22.07